Single nucleotide polymorphism near CREB1, rs7591784, is associated with pretreatment methamphetamine use frequency and outcome of outpatient treatment for methamphetamine use disorder

Journal of Psychiatric Research

Volumn 74, Issue , 2016, Pages 22-29

  Heinzerling, Keith G ^a   Demirdjian, Levon ^b   Wu, Yingnian ^b   Shoptaw, Steven ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Ancestry; CREB1; Genetics; Methamphetamine; Pharmacotherapy; Sex

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; METHAMPHETAMINE; CENTRAL STIMULANT AGENT; CREB1 PROTEIN, HUMAN;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MALE; METHAMPHETAMINE DEPENDENCE; OUTCOME ASSESSMENT; OUTPATIENT; PREMEDICATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; AMERICAN INDIAN; AMPHETAMINE DEPENDENCE; CALIFORNIA; CAUCASIAN; GENETICS; HISPANIC; SEX DIFFERENCE;

ADULT; AMPHETAMINE-RELATED DISORDERS; CALIFORNIA; CENTRAL NERVOUS SYSTEM STIMULANTS; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HISPANIC AMERICANS; HUMANS; INDIANS, NORTH AMERICAN; MALE; METHAMPHETAMINE; POLYMORPHISM, SINGLE NUCLEOTIDE; SEX FACTORS;

EID: 84958057039     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2015.12.008     Document Type: Article

References (48)

1. Bourque M., Liu B., Dluzen D.E., Di Paolo T. Sex differences in methamphetamine toxicity in mice: effect on brain dopamine signaling pathways. Psychoneuroendocrinology 2011, 36(7):955-969.
2. Brecht M.L., Herbeck D. Time to relapse following treatment for methamphetamine use: a long-term perspective on patterns and predictors. Drug Alcohol Depend. 2014, 139:18-25.
3. Brensilver M., Heinzerling K.G., Shoptaw S. Pharmacotherapy of amphetamine-type stimulant dependence: an update. Drug Alcohol Rev. 2013, 32(5):449-460.
4. Cadet J.L., Brannock C., Jayanthi S., Krasnova I.N. Transcriptional and epigenetic substrates of methamphetamine addiction and withdrawal: evidence from a long-access self-administration model in the rat. Mol. Neurobiol. 2015, 51(2):696-717.
5. Carroll K.M., Kiluk B.D., Nich C., Devito E.E., Decker S., Lapaglia D., et al. Toward empirical identification of a clinically meaningful indicator of treatment outcome: features of candidate indicators and evaluation of sensitivity to treatment effects and relationship to one year follow up cocaine use outcomes. Drug Alcohol Depend. 2014, 137c:3-19.
6. Curtin K., Fleckenstein A.E., Robison R.J., Crookston M.J., Smith K.R., Hanson G.R. Methamphetamine/amphetamine abuse and risk of Parkinson's disease in Utah: a population-based assessment. Drug Alcohol Depend. 2015, 146:30-38.
7. Dean A.C., Groman S.M., Morales A.M., London E.D. An evaluation of the evidence that methamphetamine abuse causes cognitive decline in humans. Neuropsychopharmacology 2013, 38(2):259-274.
8. Demers C.H., Bogdan R., Agrawal A. The genetics, neurogenetics and pharmacogenetics of addiction. Curr. Behav. Neurosci. Rep. 2014, 1(1):33-44.
9. Du J., Quan M., Zhuang W., Zhong N., Jiang H., Kennedy D.N., et al. Hippocampal volume reduction in female but not male recent abstinent methamphetamine users. Behav. brain Res. 2015, 289:78-83.
10. Enders C.K. Applied Missing Data Analysis 2010, Guilford Press, New York.
11. Falush D., Stephens M., Pritchard J.K. Inference of population structure using multilocus genotype data: linked loci and correlated allele frequencies. Genetics 2003, 164(4):1567-1587.
12. Glasner-Edwards S., Mooney L.J., Marinelli-Casey P., Hillhouse M., Ang A., Rawson R.A. Psychopathology in methamphetamine-dependent adults 3 years after treatment. Drug Alcohol Rev. 2010, 29(1):12-20.
13. Hart A.B., de Wit H., Palmer A.A. Candidate gene studies of a promising intermediate phenotype: failure to replicate. Neuropsychopharmacology 2013, 38(5):802-816.
14. Hart A.B., Engelhardt B.E., Wardle M.C., Sokoloff G., Stephens M., de Wit H., et al. Genome-wide association study of d-amphetamine response in healthy volunteers identifies putative associations, including cadherin 13 (CDH13). PLoS One 2012, 7(8):e42646.
15. Heinzerling K.G., Swanson A.N., Hall T.M., Yi Y., Wu Y., Shoptaw S.J. Randomized, placebo-controlled trial of bupropion in methamphetamine-dependent participants with less than daily methamphetamine use. Addiction 2014, 109(11):1878-1886.
16. Heinzerling K.G., Swanson A.N., Kim S., Cederblom L., Moe A., Ling W., et al. Randomized, double-blind, placebo-controlled trial of modafinil for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2010, 109(1-3):20-29.
17. Hillhouse M.P., Marinelli-Casey P., Gonzales R., Ang A., Rawson R.A. Predicting in-treatment performance and post-treatment outcomes in methamphetamine users. Addiction 2007, 102(Suppl. 1):84-95.
18. Jakobsson M., Rosenberg N.A. CLUMPP: a cluster matching and permutation program for dealing with label switching and multimodality in analysis of population structure. Bioinform. Oxf. Engl. 2007, 23(14):1801-1806.
19. Jones J.D., Comer S.D. A review of pharmacogenetic studies of substance-related disorders. Drug Alcohol Depend. 2015, 152:1-14.
20. Kosoy R., Nassir R., Tian C., White P.A., Butler L.M., Silva G., et al. Ancestry informative marker sets for determining continental origin and admixture proportions in common populations in America. Hum. Mutat. 2009, 30(1):69-78.
21. Krasnova I.N., Chiflikyan M., Justinova Z., McCoy M.T., Ladenheim B., Jayanthi S., et al. CREB phosphorylation regulates striatal transcriptional responses in the self-administration model of methamphetamine addiction in the rat. Neurobiol. Dis. 2013, 58:132-143.
22. Larson E.B., Graham D.L., Arzaga R.R., Buzin N., Webb J., Green T.A., et al. Overexpression of CREB in the nucleus accumbens shell increases cocaine reinforcement in self-administering rats. J. Neurosci. 2011, 31(45):16447-16457.
23. Lee B., London E.D., Poldrack R.A., Farahi J., Nacca A., Monterosso J.R., et al. Striatal dopamine d2/d3 receptor availability is reduced in methamphetamine dependence and is linked to impulsivity. J. Neurosci. 2009, 29(47):14734-14740.
24. Lee N.K., Rawson R.A. A systematic review of cognitive and behavioural therapies for methamphetamine dependence. Drug Alcohol Rev. 2008, 27(3):309-317.
25. Ma J.Z., Johnson B.A., Yu E., Weiss D., McSherry F., Saadvandi J., et al. Fine-grain analysis of the treatment effect of topiramate on methamphetamine addiction with latent variable analysis. Drug Alcohol Depend. 2013, 130(1-3):45-51.
26. McPherson S., Barbosa-Leiker C., McDonell M., Howell D., Roll J. Longitudinal missing data strategies for substance use clinical trials using generalized estimating equations: an example with a buprenorphine trial. Hum. Psychopharmacol 2013, 28(5):506-515.
27. Milesi-Halle A., Hambuchen M.D., McMillan D.E., Michael Owens S. The pharmacokinetics of methamphetamine self-administration in male and female rats. Drug Alcohol Depend. 2015, 150:164-169.
28. Nestler E.J. Cellular basis of memory for addiction. Dialogues Clin. Neurosci. 2013, 15(4):431-443.
29. Nishizawa D., Fukuda K., Kasai S., Hasegawa J., Aoki Y., Nishi A., et al. Genome-wide association study identifies a potent locus associated with human opioid sensitivity. Mol. Psychiatry 2014, 19(1):55-62.
30. Palmer R.H., Brick L., Nugent N.R., Bidwell L.C., McGeary J.E., Knopik V.S., et al. Examining the role of common genetic variants on alcohol, tobacco, cannabis and illicit drug dependence: genetics of vulnerability to drug dependence. Addiction 2015, 110(3):530-537.
31. Panenka W.J., Procyshyn R.M., Lecomte T., MacEwan G.W., Flynn S.W., Honer W.G., et al. Methamphetamine use: a comprehensive review of molecular, preclinical and clinical findings. Drug Alcohol Depend. 2013, 129(3):167-179.
32. Pritchard J.K., Stephens M., Donnelly P. Inference of population structure using multilocus genotype data. Genetics 2000, 155(2):945-959.
33. Rambousek L., Kacer P., Syslova K., Bumba J., Bubenikova-Valesova V., Slamberova R. Sex differences in methamphetamine pharmacokinetics in adult rats and its transfer to pups through the placental membrane and breast milk. Drug Alcohol Depend. 2014, 139:138-144.
34. Ray L.A., Roche D.J., Heinzerling K., Shoptaw S. Opportunities for the development of neuroimmune therapies in addiction. Int. Rev. Neurobiol. 2014, 118:381-401.
35. Roth M.E., Carroll M.E. Sex differences in the acquisition of IV methamphetamine self-administration and subsequent maintenance under a progressive ratio schedule in rats. Psychopharmacology (Berlin) 2004, 172(4):443-449.
36. Rubin D.B., Schenker N. Interval estimation from multiply-imputed data: a case study using census agriculture industry codes. J. Off. Stat 1987, 3(4):375-387.
37. Ruda-Kucerova J., Amchova P., Babinska Z., Dusek L., Micale V., Sulcova A. Sex differences in the reinstatement of methamphetamine seeking after forced abstinence in Sprague-Dawley rats. Front. Psychiatry 2015, 6:91.
38. Salamanca S.A., Sorrentino E.E., Nosanchuk J.D., Martinez L.R. Impact of methamphetamine on infection and immunity. Front. Neurosci. 2014, 8:445.
39. Shaw-Lutchman T.Z., Impey S., Storm D., Nestler E.J. Regulation of CRE-mediated transcription in mouse brain by amphetamine. Synapse (New York, NY) 2003, 48(1):10-17.
40. Stein J.L., Hibar D.P., Madsen S.K., Khamis M., McMahon K.L., de Zubicaray G.I., et al. Discovery and replication of dopamine-related gene effects on caudate volume in young and elderly populations (N=1198) using genome-wide search. Mol. Psychiatry 2011, 16(9). 927-37, 881.
41. Uhl G.R., Drgon T., Liu Q.R., Johnson C., Walther D., Komiyama T., et al. Genome-wide association for methamphetamine dependence: convergent results from 2 samples. Arch. Gen. Psychiatry 2008, 65(3):345-355.
42. Wetherill L., Agrawal A., Kapoor M., Bertelsen S., Bierut L.J., Brooks A., et al. Association of substance dependence phenotypes in the COGA sample. Addict. Biol. 2015, 20(3):617-627.
43. Wolf C., Mohr H., Diekhof E.K., Vieker H., Goya-Maldonado R., Trost S., et al. CREB1 Genotype Modulates Adaptive Reward-based Decisions in Humans. Cerebral Cortex (New York, NY: 1991) 2015.
44. Won S., Hong R.A., Shohet R.V., Seto T.B., Parikh N.I. Methamphetamine-associated cardiomyopathy. Clin. Cardiol. 2013, 36(12):737-742.
45. Wu L.T., Blazer D.G., Patkar A.A., Stitzer M.L., Wakim P.G., Brooner R.K. Heterogeneity of stimulant dependence: a national drug abuse treatment clinical trials network study. Am. J. Addict. Am. Acad. Psychiatrists Alcohol. Addict. 2009, 18(3):206-218.
46. Ystrom E., Reichborn-Kjennerud T., Neale M.C., Kendler K.S. Genetic and environmental risk factors for illicit substance use and use disorders: joint analysis of self and co-twin ratings. Behav. Genet. 2014, 44(1):1-13.
47. Zhang Y., Lv X., Bai Y., Zhu X., Wu X., Chao J., et al. Involvement of sigma-receptor in astrocyte activation induced by methamphetamine via up-regulation of its own expression. J. Neuroinflammation 2015, 12(1):29.
48. Zuloaga D.G., Johnson L.A., Agam M., Raber J. Sex differences in activation of the hypothalamic-pituitary-adrenal axis by methamphetamine. J. Neurochem. 2014, 129(3):495-508.